×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
KMDA – kamada ltd. - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
KMDA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/9
07:01 am
kmda
Kamada (NASDAQ:KMDA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Kamada (NASDAQ:KMDA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/8
07:00 am
kmda
Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026
Medium
Report
Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026
11/10
04:19 pm
kmda
Kamada Ltd (KMDA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements [Yahoo! Finance]
Low
Report
Kamada Ltd (KMDA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements [Yahoo! Finance]
11/10
07:00 am
kmda
Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth
Low
Report
Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth
11/7
07:51 am
kmda
Earnings To Watch: Kamada Ltd (KMDA) Reports Q3 2025 Result [Yahoo! Finance]
Low
Report
Earnings To Watch: Kamada Ltd (KMDA) Reports Q3 2025 Result [Yahoo! Finance]
11/4
07:00 am
kmda
Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney Transplantation
Low
Report
Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney Transplantation
11/3
07:00 am
kmda
Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025
Low
Report
Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025
10/29
07:00 am
kmda
Kamada to Present at the Stifel 2025 Healthcare Conference
Low
Report
Kamada to Present at the Stifel 2025 Healthcare Conference
Date
Time
Symbol
Company Name
Action
%Chg
11/10/2025
07:00 am
kmda
kamada ltd. - ordinary shares
MISS
Report
2.8%
kamada ltd. - ordinary shares
8/13/2025
07:00 am
kmda
kamada ltd. - ordinary shares
BEAT
Report
-1.3%
kamada ltd. - ordinary shares
5/14/2025
07:00 am
kmda
kamada ltd. - ordinary shares
IN-LINE
Report
1.3%
kamada ltd. - ordinary shares
3/5/2025
07:05 am
kmda
kamada ltd. - ordinary shares
BEAT
Report
7.9%
kamada ltd. - ordinary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/10
09:15 am
kmda
Form 6-K KAMADA LTD For: Dec 10
Low
Report
Form 6-K KAMADA LTD For: Dec 10
12/8
07:00 am
kmda
Form 6-K KAMADA LTD For: Dec 08
Medium
Report
Form 6-K KAMADA LTD For: Dec 08
12/2
07:38 am
kmda
Form 6-K/A KAMADA LTD For: Dec 02
Low
Report
Form 6-K/A KAMADA LTD For: Dec 02
11/10
07:00 am
kmda
Form 6-K KAMADA LTD For: Sep 30
Low
Report
Form 6-K KAMADA LTD For: Sep 30
11/4
07:00 am
kmda
Form 6-K KAMADA LTD For: Nov 04
Low
Report
Form 6-K KAMADA LTD For: Nov 04
10/23
07:00 am
kmda
Form 6-K KAMADA LTD For: Oct 23
Low
Report
Form 6-K KAMADA LTD For: Oct 23
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/21
Form 6-K KAMADA LTD For: Nov 21
13.5%
1/21 Kamada Announces $25 Million Private Placement with FIMI Opportunity Fund 6.4%
12/9 Kamada Enters into a Binding Term Sheet for Contract Manufacturing of an FDA Approved, Commercialized Hyper-Immune Globulin Product 4.5%
11/13 Q3/2019 9/30/2019 EPS 0.140 ZacksConsensus 0.090 ActVsEst 0.050 - Beat 3.9%
2/5 Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2019 Financial Results and Host Conference Call on February 12, 2020 3.2%
11/12 Form 6-K KAMADA LTD For: Nov 12 2.7%
12/4 Form 6-K KAMADA LTD For: Dec 04 2.2%
10/25 Kamada Ltd. (NASDAQ: KMDA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 2.0%
11/7 Kamada to Report Third Quarter 2019 Financial Results and Host Conference Call on November 13 1.3%
2/19 Kamada Ltd. (NASDAQ: KMDA) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 1.3%
1/21 Kamada Announces $25 Million Private Placement with FIMI Opportunity Fund 6.4%
12/9 Kamada Enters into a Binding Term Sheet for Contract Manufacturing of an FDA Approved, Commercialized Hyper-Immune Globulin Product 4.5%
11/13 Q3/2019 9/30/2019 EPS 0.140 ZacksConsensus 0.090 ActVsEst 0.050 - Beat 3.9%
2/5 Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2019 Financial Results and Host Conference Call on February 12, 2020 3.2%
11/12 Form 6-K KAMADA LTD For: Nov 12 2.7%
12/4 Form 6-K KAMADA LTD For: Dec 04 2.2%
10/25 Kamada Ltd. (NASDAQ: KMDA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 2.0%
11/7 Kamada to Report Third Quarter 2019 Financial Results and Host Conference Call on November 13 1.3%
2/19 Kamada Ltd. (NASDAQ: KMDA) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 1.3%
TOP News Decliners
3/11
Kamada Provides Update on Progress Related to its Proprietary Hyper-Immunoglobulin (IgGs) Platform Technology including its Commercial Anti-Rabies IgG and its Pipeline Products Anti-Corona (COVID-19) and Anti-Zika IgGs
-14.2%
2/12 Q4/2019 12/31/2019 EPS 0.130 ZacksConsensus 0.130 ActVsEst 0.000 - In-Line -8.2%
2/18 Form SC 13G/A KAMADA LTD Filed by: MEITAV DASH INVESTMENTS LTD -7.4%
1/7 Kamada Announces Preliminary Revenue for Fourth Quarter and Full-Year 2019 and Provides Full-Year 2020 Revenue Guidance -5.4%
1/9 Kamada Ltd. (NASDAQ: KMDA) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -4.3%
12/2 Form SC 13D/A KAMADA LTD Filed by: Brosh Capital Partners L.P. -3.9%
12/16 Kamada Announces Enrollment of First Patient into its Pivotal Phase 3 InnovAATe Clinical Trial of Inhaled AAT for the Treatment of Alpha-1 Antitrypsin Deficiency -3.8%
1/24 Kamada Ltd. (NASDAQ: KMDA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -3.7%
10/29 Kamada and Kedrion Biopharma Announce Publication of Results from the Registration Study of KEDRAB® (Rabies Immune Globulin [Human]) in Human Vaccines & Immunotherapeutics Medical Journal -3.6%
12/23 Kamada Ltd. (NASDAQ: KMDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock. -3.0%
2/12 Q4/2019 12/31/2019 EPS 0.130 ZacksConsensus 0.130 ActVsEst 0.000 - In-Line -8.2%
2/18 Form SC 13G/A KAMADA LTD Filed by: MEITAV DASH INVESTMENTS LTD -7.4%
1/7 Kamada Announces Preliminary Revenue for Fourth Quarter and Full-Year 2019 and Provides Full-Year 2020 Revenue Guidance -5.4%
1/9 Kamada Ltd. (NASDAQ: KMDA) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -4.3%
12/2 Form SC 13D/A KAMADA LTD Filed by: Brosh Capital Partners L.P. -3.9%
12/16 Kamada Announces Enrollment of First Patient into its Pivotal Phase 3 InnovAATe Clinical Trial of Inhaled AAT for the Treatment of Alpha-1 Antitrypsin Deficiency -3.8%
1/24 Kamada Ltd. (NASDAQ: KMDA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -3.7%
10/29 Kamada and Kedrion Biopharma Announce Publication of Results from the Registration Study of KEDRAB® (Rabies Immune Globulin [Human]) in Human Vaccines & Immunotherapeutics Medical Journal -3.6%
12/23 Kamada Ltd. (NASDAQ: KMDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock. -3.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: